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Abstract
Background: Precise knowledge of axillary lymph node status is essential in the treatment of
operable carcinoma of the breast. For many years, axillary nodal clearance (ANC) has been an
integral part of the conventional management of early-stage breast cancer. During the last few
decades the trend of these surgical procedures has been one of decreasing invasiveness in order
to try and achieve a much lower level of morbidity. To help reach this improved level of treatment
the concept of the sentinel lymph node (SLN) was utilized. Recent studies have shown that SNB
can provide an accurate assessment of the axillary nodal status in clinically node negative patients,
negating the need to remove the majority of the axillary contents and thus reducing morbidity. A
recent meta-analysis of all the literature to date appears to reveal that the dual technique (blue dye
and technetium-labelled sulfur) is the gold-standard for successful identification of the SLN in the
context of early-stage breast cancer. We aim to highlight the on-going wide range of differing
methods employed, and compare this to the gold-standard recommended guidelines.
Methods:  A questionnaire was devised to provide a snapshot overview of the current
management of the axilla in patients with clinically node-negative T1 invasive breast cancer amongst
UK beast surgeons in August 2006.
Results: Of the 271 UK surgeons, 74 (27.3%) performed ANC as the initial management of the
axilla in patients with clinically node negative T1 invasive breast cancer, 56 (20.7%) used axillary
node sampling (not directed by sentinel node mapping) and a total of 141 (52.0%) used the
technique of SNB, of which 50 (18.5%) used blue dye alone and 91 (33.6%) used a combination of
blue dye and radioisotope.
Conclusion: Despite the obvious advantages, our survey has revealed that the procedure is only
used by 52% of British breast surgeons in this subgroup of patients (clinically node negative, tumour
equal of smaller than 2 cm) most of whom have no disease within the axilla. The reasons for this
include limited hospital resources and lack of surgeons training and accreditation and ARSAC
license (nuclear medicine license).
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Background
Precise knowledge of axillary lymph node status is essen-
tial in the treatment of operable carcinoma of the breast
for a number of reasons. In the first instance it permits the
accurate staging of the cancer and aids in the selection of
optimal adjuvant therapy. In fact it can be considered to
be one of the most important prognostic indicators of dis-
ease outcome in women with early breast cancer [1,2].
Patients with histologically involved lymph nodes can
anticipate a survival in the region of 50% [2]. For many
years, axillary nodal clearance (ANC) has been an integral
part of the conventional management of early-stage breast
cancer. During the last few decades the trend of these sur-
gical procedures has been one of decreasing invasiveness
in order to try and achieve a much lower level of morbid-
ity. To help reach this improved level of treatment the
concept of the sentinel lymph node (SLN) was utilized.
Since the introduction of sentinel node biopsy (SNB) in
the mid 1990's, the optimal management of the axilla in
breast cancer patients has become an issue [3]. Recent
studies have shown that SNB can provide an accurate
assessment of the axillary nodal status in clinically node
negative patients, negating the need to remove the major-
ity of the axillary contents [4,5]. In addition, the accuracy
of SNB has been well documented, with recent large stud-
ies reporting false negative rates in the range of 2–5% [1,6-
10]. The advantage of SNB in comparison to ANC is the
significant reduction in long-term morbidity associated
with the reduced level of tissue trauma [11]. Prospective
observational studies have shown no increased incidence
of axillary recurrence and confirmed the negligible mor-
bidity associated with the SNB technique [9,12]. An up to
date literature review reveals many studies are recom-
mending SNB as the optimal management of the axilla in
early stage breast cancer [11,13,19-21]. The aim of this
nationwide study is to identify the current management of
the axilla in patients with T1, clinically node negative
breast cancers by UK breast surgeons. We aim to highlight
the on-going wide range of differing methods employed,
and compare this to the gold-standard recommended
guidelines.
Methods
A questionnaire was devised to provide a snapshot over-
view of the current management of the axilla in patients
with clinically node-negative T1 invasive breast cancer
amongst UK beast surgeons in August 2006. This was dis-
tributed to all breast surgeons listed in the Royal College
of Surgeons database (n = 403). Three questions were pro-
posed: initial procedure performed (ANC, axillary node
sampling or SNB), the use of intraoperative frozen section
or cytology and the further management plan if the SNB
or axillary node sample was identified to contain tumour
cells (radiotherapy versus ANC). Importantly we subdi-
vided the initial question to identify how many surgeons
used blue dye alone and how many utilized the dual tech-
nique (radioactive isotope and blue dye) in view of the
current literature recommendations.
Results
A total of 271 (67.2%) completed questionnaires were
received. Of the 271 UK surgeons, 74 (27.3%) performed
ANC as the initial management of the axilla in patients
with clinically node negative T1 invasive breast cancer, 56
(20.7%) used axillary node sampling (not directed by sen-
tinel node mapping) and a total of 141 (52.0%) used the
technique of SNB, of which 50 (18.5%) used blue dye
alone and 91 (33.6%) used a combination of blue dye
and radioisotope. Amongst the surgeons who performed
SNB using blue dye alone 26 also sent an additional four-
node sample. 13 of the surgeons using the dual technique
for sentinel node biopsy also did this.
With regards to the use of intra-operative examination, 7
surgeons (2.58%) used intraoperative frozen section to
identify malignant cells within axillary lymph nodes, and
8 (2.95%) used cytological techniques. One surgeon used
both frozen section and intraoperative cytology.
Amongst the 197 (72.7%) surgeons who did not under-
take ANC as the initial management of clinically node-
negative T1 invasive breast cancer, 124 (62.9%) pro-
ceeded directly to axillary node clearance if the sentinel
node biopsy or four-node sample was positive for malig-
nancy. However 31 (15.7%) completed treatment with
radiotherapy alone. 8 (4.06%) used both axillary node
clearance and radiotherapy. 33 (16.8%) used either axil-
lary node clearance or radiotherapy dependent on a
number of factors including extent of disease/number of
positive nodes on axillary sampling, histological grade of
the breast cancer, patient preference and general health/
co-morbidities of the patient involved.
Discussion
By definition, the sentinel node is the first node to which
lymphatic drainage from the breast reaches. Thus these
nodes are the most likely to harbor tumour cells if a breast
cancer has indeed entered the lymphatics. These are usu-
ally located within the axilla, cranial to the intercostobra-
chial nerve, within 2 cm of the lateral edge to the
pectoralis minor muscle [14]. However they may be
found as an internal mammary node, a supraclavicular
node or even a contralateral axillary node. The latter are
very unusual. A tracer substance (a radioactive isotope,
blue dye, and often both) injected into the breast provides
a roadmap leading to the SLN(s). This follows the premise
that the material (dye) will migrate through the lymphat-
ics of the breast to the first lymph node(s) draining the
tumour. These nodes are then removed and examinedInternational Seminars in Surgical Oncology 2007, 4:4 http://www.issoonline.com/content/4/1/4
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microscopically for the presence of metastatic tumour
cells, often by frozen section techniques.
The SLN concept was initially introduced by Cabanas in
1977 [15]. He applied it to the management of penile can-
cer. The technique was popularised in the 1980s and early
1990s in the management of melanoma by Morton et al
[16]. They used the injection of isosulfan blue dye to
allow visualisation as it flowed through and stained lym-
phatic channels and nodes, enabling identification, exci-
sion and assessment of blue-stained nodes. In the early
1990s the SLN concept was applied to the management of
breast cancer patients. These initial efforts followed the
progress made in the management of melanoma, pre-
dominantly with the use of both radiotracer and blue-dye
techniques to help identify the SLN. The first description
of the use of SNB within the context of breast cancer was
by Krag et al in 1993 [14].
International acceptance of the SNB over routine ANC is
based on several considerations. In the first instance it is a
much less invasive procedure that may be performed
under local anaesthesia, often on an outpatient basis. It is
well documented that it is associated with a much lower
risk of common morbidities which are recognized features
of full ANC. The results of the ALMANAC (a large prospec-
tive randomized control trial) support the use of SNB in
patients with clinically node negative beast cancer in view
of the benefits regarding arm functioning and quality of
life [21]. In addition, the SNB allows the pathologist to
study the few SLNs in greater detail compared with the
larger number of lymph nodes removed in ANC. This
leads to a greater degree of accuracy.
The SNB remains to be standardized universally; the
methods, materials and patient selection vary by institu-
tion and surgeon. Identification of the SLN using 99 m-
technetium-labelled sulfur was shown to be successful by
Krag et al [3]. Giulian et al [14] demonstrated the same
findings using blue dye and Albertini et al [17] used the
dual technique, i.e. a combination of the two. Initial iden-
tification rates were reported at 82%, 66% and 92%
respectively [3,14,17]. A recent meta-analysis of all the lit-
erature to date appears to reveal that the dual technique is
the gold-standard for successful identification of the SLN
in the context of early-stage breast cancer [18].
A study by Smidt et al from 1998 to 2003 [22] revealed
that although axillary recurrences after a negative SNB do
occur, this is at a much lower rate than would be expected
on the basis of histological figures and the false negative
SLN findings. The axillary recurrence rate in the literature
is quoted as 0.25% [22]. Following review of the results of
this study, the natural history of axillary relapse after neg-
ative SNB resembles the locoregional recurrence of breast
cancer [22].
In comparison to the success of SNB, ANC appears to have
a limited role in the initial management of early stage
breast cancer. The majority (in the region of 70%) of
women with clinically node negative axilla will prove to
be microscopically negative as well [13]. As mentioned
previously the ALMANAC study performed in the United
Kingdom has shown that compared with standard treat-
ment, SNB is quicker, does not require drain usage, is
associated with a shorter hospital stay but more impor-
tantly, it significantly reduces the morbidity for the
patient. The SNB is gradually becoming a new standard of
care in patients with early breast cancer. However certain
criteria should be fulfilled for its safe application. Despite
the obvious advantages, our survey has revealed that the
procedure is only used by 52% of British breast surgeons
in this subgroup of patients (clinically node negative,
tumour equal of smaller than 2 cm) most of whom have
no disease within the axilla. This percentage is well below
that reported in a similar study in the USA (74% in 2001
and likely to be much higher now) [23]. Of these Ameri-
can surgeons, 89% used both sulfur colloid radioisotope
and isosulfan blue dye. This can be compared to only
33.6% (64.5% of those that perform the SNB) of British
surgeons utilizing this optimal approach [24]. Intra-oper-
ative assessment of the sentinel lymph node is performed
by a minority of British surgeons. This is most likely to be
the consequence of limited resources. The implication of
this finding is that a significant number of patients are
undergoing a second surgical procedure if the SNB is
found to contain malignant cells.
The reasons for the low percentage of British breast sur-
geons performing SNB include limited hospital resources
and lack of surgeons' training and accreditation and
ARSAC license (nuclear medicine license). The National
Health Service (NHS) focuses on targets and the financial
difficulties encountering most NHS hospitals are contrib-
uting to the low prevalence of the optimal application of
this procedure. Hospitals and surgeons should therefore
be encouraged to make the optimal technique of SNB
available to their patients as a good alternative to ANC.
The SNB in breast cancer training course (NEW START) is
a unique team-based national training programme in the
technique comprising theoretical teaching lasting one day
and on-site proctored training. A validation series of 30
cases, which is audited centrally, is performed by each sur-
geon participating. Despite the figures produced from this
survey, the prevalence of the SNB in the UK should
improve over the next few years. NEW START has current
data on over 2500 patients in the programme (all using
isotope), thus there are 80–100 surgeons currently in
training with an estimated 80% of British hospitals thatInternational Seminars in Surgical Oncology 2007, 4:4 http://www.issoonline.com/content/4/1/4
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have signed up for training but have yet all to complete
their validation phase. The programme has now become
international with training taking place in Norway and
India, with visits planned for China next year.
Within this survey we did not investigate the use of rou-
tine preoperative lymphoscintigraphy to facilitate sentinel
node identification. However recent studies [25] suggest
that although it may be valuable for surgeons within the
learning phase or in patients who have increased risk of
intraoperative failed localisation (obese or elderly
patients), this step is not essential to successful SNB given
the time and cost required to perform this. In addition we
did not examine the practice patterns of internal mam-
mary dissection due to the lack of conclusive evidence that
this procedure has a significant clinical benefit [26].
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